Cisplatin
Cisplatin and weekly docetaxel evaluated in phase II study
Published in Cancer Weekly, August 16th, 2005
According to recent research published in the journal Tumori, "Based on the results of previous phase I studies, in the current phase II trial we evaluated the efficacy and toxicity of cisplatin plus weekly docetaxel in the treatment of advanced non-small cell lung cancer (NSCLC). The eligibility criteria for the study included newly diagnosed stage IIIB/IV NSCLC, age {{<=}}75 years, Eastern Cooperative Oncology Group performance status of 0-2, adequate organ functions, and signed informed consent."
"The chemotherapy regimen consisted of cisplatin, 80 mg/m2 on day...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-08-16)
More Articles from Cancer Weekly
- Cognitive Science
Cancer listed as risk factor for long-term cognitive deficits and dementia - Coping Strategies
Social support and hopelessness examined in Turkish cancer patients - Drug Development
Continuous toxicity monitoring advised in oncologic phase II trials - Epidemiology
Correctable sources of disparities in cancer among minority elders identified - Prostate Cancer
Pilot study aimed to determine support during pre-treatment of prostate cancer - Actin
SPECs examined, role in synapse F-actin accumulation clarified - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
